Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unlicensed by the MHRA or EMA and still being evaluated in Phase 2 and Phase 3 clinical trials
Medically reviewed by Tarun Kumar, Prescribing Pharmacist (GPhC 2233073) Last reviewed: 25 June 2026 Quick Summary Retatrutide is a triple incretin receptor agonist being studied as a once-weekly injectable treatment for obesity
Medications You Can Trust: Our medication plans include access to name-brand prescriptions as well as compounded Semaglutide and Tirzepatide , based on patient preference and medical necessity
Similar combinations of active biological agents might minimise the unwanted cardiovascular effects of traditional small-molecule-based drugs or target anti-inflammatory pharmacology to only certain select tissues
According to the American Diabetes Association (ADA) Standards of Care, GLP-1 receptor agonists with proven cardiovascular benefit are recommended for many patients with type 2 diabetes who have established cardiovascular disease, with individualized therapy based on patient factors
Moringa Magic and Digestive Health: How It Supports a Balanced Gut A well-functioning digestive system is foundational to overall health, influencing everything from nutrient absorption to immune function
00092-0/asset/68240365-3bb7-461d-91f9-d644c6b9c749/main.assets/gr3.jpg)
